JP2016513097A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513097A5
JP2016513097A5 JP2015556938A JP2015556938A JP2016513097A5 JP 2016513097 A5 JP2016513097 A5 JP 2016513097A5 JP 2015556938 A JP2015556938 A JP 2015556938A JP 2015556938 A JP2015556938 A JP 2015556938A JP 2016513097 A5 JP2016513097 A5 JP 2016513097A5
Authority
JP
Japan
Prior art keywords
composition
albumin
composition according
paclitaxel
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015556938A
Other languages
English (en)
Japanese (ja)
Other versions
JP6388880B2 (ja
JP2016513097A (ja
Filing date
Publication date
Priority claimed from US13/791,841 external-priority patent/US9149455B2/en
Application filed filed Critical
Priority claimed from PCT/US2013/072877 external-priority patent/WO2014123612A1/en
Publication of JP2016513097A publication Critical patent/JP2016513097A/ja
Publication of JP2016513097A5 publication Critical patent/JP2016513097A5/ja
Application granted granted Critical
Publication of JP6388880B2 publication Critical patent/JP6388880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015556938A 2013-02-11 2013-12-03 メラノーマの治療方法 Active JP6388880B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361763391P 2013-02-11 2013-02-11
US61/763,391 2013-02-11
US13/791,841 2013-03-08
US13/791,841 US9149455B2 (en) 2012-11-09 2013-03-08 Methods of treating melanoma
PCT/US2013/072877 WO2014123612A1 (en) 2013-02-11 2013-12-03 Methods of treating melanoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017214523A Division JP6470381B2 (ja) 2013-02-11 2017-11-07 メラノーマの治療方法

Publications (3)

Publication Number Publication Date
JP2016513097A JP2016513097A (ja) 2016-05-12
JP2016513097A5 true JP2016513097A5 (cg-RX-API-DMAC7.html) 2017-01-12
JP6388880B2 JP6388880B2 (ja) 2018-09-12

Family

ID=51300036

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015556938A Active JP6388880B2 (ja) 2013-02-11 2013-12-03 メラノーマの治療方法
JP2017214523A Active JP6470381B2 (ja) 2013-02-11 2017-11-07 メラノーマの治療方法
JP2019006038A Withdrawn JP2019056014A (ja) 2013-02-11 2019-01-17 メラノーマの治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017214523A Active JP6470381B2 (ja) 2013-02-11 2017-11-07 メラノーマの治療方法
JP2019006038A Withdrawn JP2019056014A (ja) 2013-02-11 2019-01-17 メラノーマの治療方法

Country Status (13)

Country Link
EP (1) EP2953622B1 (cg-RX-API-DMAC7.html)
JP (3) JP6388880B2 (cg-RX-API-DMAC7.html)
KR (1) KR102148551B1 (cg-RX-API-DMAC7.html)
CN (2) CN109200031A (cg-RX-API-DMAC7.html)
BR (1) BR112015019064A8 (cg-RX-API-DMAC7.html)
CA (1) CA2900668A1 (cg-RX-API-DMAC7.html)
ES (1) ES2872328T3 (cg-RX-API-DMAC7.html)
HK (1) HK1218506A1 (cg-RX-API-DMAC7.html)
IL (1) IL240388B (cg-RX-API-DMAC7.html)
MX (1) MX377729B (cg-RX-API-DMAC7.html)
NZ (1) NZ630239A (cg-RX-API-DMAC7.html)
WO (1) WO2014123612A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201505956B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105147613A (zh) 2010-03-29 2015-12-16 阿布拉科斯生物科学有限公司 增强药物递送和治疗剂有效性的方法
RU2016119999A (ru) 2010-03-29 2018-11-08 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения онкологических заболеваний
EP2707030B1 (en) 2011-05-09 2020-02-19 Mayo Foundation For Medical Education And Research Cancer treatments
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
WO2014055415A1 (en) 2012-10-01 2014-04-10 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
CN105246468A (zh) 2013-03-14 2016-01-13 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
EA201692502A1 (ru) 2014-06-16 2017-09-29 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Лечение миелом
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
CN113599534A (zh) * 2014-10-06 2021-11-05 梅约医学教育与研究基金会 载体-抗体组合物及其制备和使用方法
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
AU2016285720C1 (en) 2015-06-29 2022-02-03 Abraxis Bioscience, Llc Methods of treating epithelioid cell tumors
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體-抗體組合物及其製造及使用方法
CN114796130B (zh) * 2015-08-18 2023-10-20 梅约医学教育与研究基金会 载体结合剂组合物及其制备和使用方法
TW201713360A (en) * 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CA3014531A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
CA3018341A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
KR102462041B1 (ko) * 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체-pd-l1 결합제 조성물
JP7025412B2 (ja) 2016-09-06 2022-02-24 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パクリタキセル-アルブミン-結合剤組成物並びに該組成物の使用及び製造方法
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
CA3076919A1 (en) 2017-10-03 2019-04-11 Crititech, Inc. Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer
SG11202009145PA (en) 2018-03-20 2020-10-29 Abraxis Bioscience Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
WO2021086946A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
SI1585548T1 (sl) 2002-12-09 2018-11-30 Abraxis Bioscience, Llc Sestave in metode odmerjanja farmakoloških sredstev
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
SI2301531T1 (sl) * 2005-02-18 2018-11-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
CA2620389C (en) 2005-08-31 2014-06-17 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20080045589A1 (en) * 2006-05-26 2008-02-21 Susan Kelley Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
NZ593343A (en) * 2008-12-11 2013-04-26 Abraxis Bioscience Llc Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
WO2012048223A1 (en) * 2010-10-08 2012-04-12 Abraxis Bioscience, Llc Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP2016513097A5 (cg-RX-API-DMAC7.html)
JP2013523656A5 (cg-RX-API-DMAC7.html)
JP2016513075A5 (cg-RX-API-DMAC7.html)
JP2018111728A5 (cg-RX-API-DMAC7.html)
JP2013503174A5 (cg-RX-API-DMAC7.html)
JP2016506908A5 (cg-RX-API-DMAC7.html)
JP2016512506A5 (cg-RX-API-DMAC7.html)
JP2012506448A5 (cg-RX-API-DMAC7.html)
JP2016505018A5 (cg-RX-API-DMAC7.html)
JP2019519519A5 (cg-RX-API-DMAC7.html)
JP2010509331A5 (cg-RX-API-DMAC7.html)
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
CO6260019A2 (es) Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento
Vanić et al. Nanomedicines for the topical treatment of vulvovaginal infections: Addressing the challenges of antimicrobial resistance
JP2010514787A5 (cg-RX-API-DMAC7.html)
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
JP2011511072A5 (cg-RX-API-DMAC7.html)
NZ708506A (en) Methods of treating bladder cancer
EA200701195A1 (ru) Содержащие цефалоспорин композиции с наночастицами и с контролируемым высвобождением
JP2016515586A5 (cg-RX-API-DMAC7.html)
JP2013527233A5 (cg-RX-API-DMAC7.html)
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
HRP20250141T1 (hr) Nanočestice koje sadrže sirolimus i albumin za upotrebu u liječenju tumora epiteloidnih stanica
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
NO20091191L (no) Fremgangsmater for behandling av kreft, innbefattende administrering av et vitamin D preparat og et ytterligere terapeutisk middel, og sammensetninger som inneholder de samme